nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

23.10.2023 | Editorial

New opportunities for dosimetric approach in patients with differentiated thyroid cancer

verfasst von: Leandra Piscopo, Emilia Zampella, Michele Klain

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Excerpt

In the adult population, the differentiated thyroid cancer (DTC) is the most frequent endocrine neoplasm [1]. …

Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133. https://doi.org/10.1089/thy.2015.0020.CrossRefPubMedPubMedCentral

Klain M, Nappi C, Zampella E, Cantoni V, Green R, Piscopo L, et al. Ablation rate after radioactive iodine therapy in patients with differentiated thyroid cancer at intermediate or high risk of recurrence: a systematic review and a meta-analysis. Eur J Nucl Med Mol Imaging. 2021;48(13):4437–44. https://doi.org/10.1007/s00259-021-05440-x.CrossRefPubMedPubMedCentral

Klain M, Pace L, Zampella E, Mannarino T, Limone S, Mazziotti E, et al. Outcome of patients with differentiated thyroid cancer treated with 131-iodine on the basis of a detectable serum thyroglobulin level after initial treatment. Front Endocrinol (Lausanne). 2019;12(10):146. https://doi.org/10.3389/fendo.2019.00146.CrossRef

Zampella E, Piscopo L, Manganelli M, Volpe F, Nappi C, Gaudieri V, et al. Prognostic value of 12-month response to therapy in pediatric patients with differentiated thyroid cancer. Endocrine. 2023;80(3):612–8. https://doi.org/10.1007/s12020-023-03309-7.CrossRefPubMedPubMedCentral

Klain M, Zampella E, Manganelli M, Gaudieri V, Nappi C, D’Antonio A, et al. Risk of structural persistent disease in pediatric patients with low or intermediate risk differentiated thyroid cancer. Endocrine. 2021;71(2):378–84. https://doi.org/10.1007/s12020-020-02379-1.CrossRef

Francis GL, Waguespack SG, Bauer AJ, Angelos P, Benvenga S, Cerutti JM, et al. American Thyroid Association guidelines task force. Management guidelines for children with thyroid nodules and differentiated thyroid cancer. Thyroid. 2015;25(7):716–59. https://doi.org/10.1089/thy.2014.0460.

Piscopo L, Zampella E, Volpe F, Gaudieri V, Nappi C, Cutillo P, et al. Efficacy of empirical radioiodine therapy in patients with differentiated thyroid cancer and elevated serum thyroglobulin without evidence of structural disease: a propensity score analysis. Cancers (Basel). 2023;15(16):4196. https://doi.org/10.3390/cancers15164196.CrossRefPubMed

Porcelli T, Luongo C, Sessa F, Klain M, Masone S, Troncone G, et al. Long-term management of lenvatinib-treated thyroid cancer patients: a real-life experience at a single institution. Endocrine. 2021;73(2):358–66. https://doi.org/10.1007/s12020-021-02634-z.CrossRefPubMed

Nersita R, Matrone A, Klain M, Scavuzzo F, Vitolo G, Abbondanza C, et al. Decreased serum vascular endothelial growth factor-D levels in metastatic patients with differentiated thyroid carcinoma. Clin Endocrinol (Oxf). 2012;76(1):142–6. https://doi.org/10.1111/j.1365-2265.2011.04183.CrossRef

10.

Nappi C, Klain M, Cantoni V, Green R, Piscopo L, Volpe F, et al. Risk of primary breast cancer in patients with differentiated thyroid cancer undergoing radioactive iodine therapy: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2022;49(5):1630–9. https://doi.org/10.1007/s00259-021-05625-4.CrossRef

11.

Piscopo L, Volpe F, Nappi C, Zampella E, Manganelli M, Matrisciano F, et al. Second primary malignancies in patients with differentiated thyroid cancer after radionuclide therapy: a retrospective single-centre study. Curr Oncol. 2022;30(1):37–44. https://doi.org/10.3390/curroncol30010003.CrossRefPubMedCentral

12.

Bianco D, Nappi C, Piscopo L, Volpe F, Manganelli M, Volpicelli F, et al. Initial testing of an approximated, fast calculation procedure for personalized dosimetry in radionuclide therapy based on planar whole-body scan and Monte-Carlo specific dose rates from the open dose project. Life (Basel). 2022;12(9):1303. https://doi.org/10.3390/life12091303.CrossRefPubMed

13.

Klain M, Nappi C, De Risi M, Piscopo L, Volpe F, Manganelli M, et al. Whole-body radioiodine effective half-life in patients with differentiated thyroid cancer. Diagnostics (Basel). 2021;11(10):1740. https://doi.org/10.3390/diagnostics11101740.CrossRefPubMed

14.

Giovanella L, Lassmann M. Radioiodine dosimetry in advanced thyroid cancer. Q J Nucl Med Mol Imaging. 2019;63(3):227–8. https://doi.org/10.23736/S1824-4785.19.03209-6.CrossRefPubMed

15.

Taprogge J, Vergara-Gil A, Leek F, Abreu C, Vávrová L, Carnegie-Peake L, et al. Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD project. Eur J Nucl Med Mol Imaging. 2023;50(11):3225–34. https://doi.org/10.1007/s00259-023-06295-0.CrossRefPubMedPubMedCentral

16.

Assante R, Zampella E, Nicolai E, Acampa W, Vergara E, Nappi C, et al. Incremental value of sestamibi SPECT/CT over dual-phase planar scintigraphy in patients with primary hyperparathyroidism and inconclusive ultrasound. Front Med (Lausanne). 2019;16(6):164. https://doi.org/10.3389/fmed.2019.00164.CrossRef

Titel: New opportunities for dosimetric approach in patients with differentiated thyroid cancer
verfasst von: Leandra Piscopo
Emilia Zampella
Michele Klain
Publikationsdatum: 23.10.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 2/2024
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-023-06473-0

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

New opportunities for dosimetric approach in patients with differentiated thyroid cancer

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2024

Why chose nuclear medicine: the journey of two medical imaging students in China

The first international network symposium on artificial intelligence and informatics in nuclear medicine: “The bright future of nuclear medicine is illuminated by artificial intelligence”

The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy

Development and performance of SIAT bPET: a high-resolution and high-sensitivity MR-compatible brain PET scanner using dual-ended readout detectors

Abdelhamid H. Elgazzar, Synopsis of Pathophysiology in Nuclear Medicine, Second Edition

Comparison of parametric imaging and SUV imaging with [68 Ga]Ga-PSMA-11 using dynamic total-body PET/CT in prostate cancer